Key Players - Macular Degeneration Treatment Industry

 

Macular degeneration, an eye condition that damages the macula, causes central vision loss as one of its symptoms (the centre of the light-sensitive retina at the back of the eye). Central vision becomes hazy as a result of an eye condition known as AMD. It happens when ageing damages the macula, which is a component of the retina, the light-sensitive tissue in the rear of the eye. There are two types of age-related macular degeneration: dry and wet. The most typical form of AMD is dry AMD. The macula becomes thinner at this point as we age. Dry macular degeneration is a prevalent eye disorder that affects persons over 50. Wet AMD is characterised by leaky blood vessels in the eye, which leads to a rapid and progressive loss of central vision.

The global Macular Degeneration Treatment Market was estimated to be worth US$ 8,208.7 Mn in 2021 and is anticipated to grow at a 7.0% CAGR from 2022 to 2028 to reach US$ 13,195.7 Mn.

Prominent Companies in the Macular Degeneration Treatment Industry:

1. F. Hoffmann-La Roche-

Roche is the brand name for F. Hoffmann-La Roche AG, a global healthcare conglomerate with two divisions: pharmaceuticals and diagnostics. Shares of Roche Holding AG, its holding company, are traded on the SIX Swiss Exchange. Basel is where the corporate headquarters are situated. On October 1, 1896, Hoffmann-La Roche & Co. was established at a period when the industrial revolution was reshaping Europe. The Roche Group, with its headquarters in Basel, Switzerland, operates in more than 100 nations and will have more than 100,000 employees by the year 2020. Roche today announced the availability of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody in 2023, both of which will be used to determine the status of mutations in patients with brain cancer.

2.Novartis-

In March 1996, Ciba-Geigy and Sandoz Laboratories, two Swiss businesses, merged to form Novartis. It is a Swiss international pharmaceutical firm with offices in Cambridge, Massachusetts and Basel, Switzerland (global research). One of the biggest pharmaceutical firms in the world, Novartis was the fourth largest by sales in 2022 and has consistently been rated in the top five globally. Novartis was founded with the goal of fostering innovation and establishing an even more powerful presence on the world markets. As a preeminent global pharmaceutical firm, we develop game-changing therapies in areas of urgent medical need using cutting-edge research and digital technology. To enhance and lengthen people's lives, Novartis is rethinking medicine.

3.Pfizer Inc.-

Constructed in 1849 Pfizer Inc. is a worldwide pharmaceutical and biotechnology company with its main office in Manhattan, New York City, on 42nd Street. India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US are all home to significant manufacturing facilities for it. The company sells its goods across the Middle East, North America, South America, Australia, Asia-Pacific, Europe, and Africa. In the US, New York serves as the home of Pfizer. It conducts business as a pharmaceutical firm. For oncology, inflammatory, cardiology, and other therapeutic areas, the company provides medications, vaccines, medical devices, and consumer healthcare goods. Worldwide customers are served by Pfizer. Pfizer received favourable FDA Advisory Committee votes on 02.28.2023 in support of the potential approval of a vaccine candidate to help treat RSV in elderly people.

4.PanOptica-

Founded in 2009, PanOptica is a biopharma firm that creates ophthalmic therapies to treat eye ailments. Mount Arlington(HQ), New Jersey, in the United States, is where PanOptica is based. It is a creative production firm with a focus on branded, original, and commercial content. The firm currently offers therapies that are successful at delaying vision loss and may even enhance vision in some patients, but to achieve the best results, many patients need regular, chronic intraocular injections and close monitoring. People who quit their treatments risk losing their vision permanently.

5.Bausch Health Companies Inc.-

A international specialised pharmaceutical firm with headquarters in Laval, Quebec, Canada is Bausch Health Companies Inc. It creates, produces, and sells pharmaceutical goods and name-brand generic medications, primarily for eye health, neurology, gastrointestinal disorders, and skin conditions. The business was founded in 1959 and is headquartered in Laval, Canada. The corporation sells its goods either directly or indirectly in a number of different parts of the world, including the US, Canada, Europe, Australia, Africa, the Middle East, and Australia. Nowadays, a variety of businesses with a focus on dermatology, gastrointestinal, neurology, and worldwide pharmaceuticals make up Bausch Health.

6. Regeneron Pharmaceuticals, Inc.—

The corporate headquarters of the American biotechnology firm Regeneron Pharmaceuticals, Inc. are in Westchester County, New York. The business was established in 1988. In Tarrytown, New York, in the United States, it has its headquarters. All of the medications are produced throughout our manufacturing footprint in Raheen, Ireland and Rensselaer, New York, whether they are for a clinical trial or a commercial market. Many FDA-approved therapies and product candidates are being developed as a result of Regeneron's exceptional capacity to consistently and repeatedly transfer research into medicine.

7.Aerie Pharmaceuticals Inc.-

Aerie Pharmaceuticals Inc., founded on January 1, 2005, is a clinical-stage pharmaceutical business focused on the discovery, development, and commercialization of treatments for the treatment of people with glaucoma and other eye illnesses. Durham, North Carolina serves as the corporate headquarters for Aerie Pharmaceuticals. Europe, the Commonwealth of Independent States, China, India, a portion of South America, and the countries of Oceania are all covered by the company's agreement. Current third quarter Glaucoma Franchise Net Revenues of $36.1 million, up 23% from third quarter 2021 Agreement to be Purchased by Alcon; Deal Expected to Complete in the Fourth Quarter of 2022 DURRHAM, N.C.

8.REGENX inc-

Leading clinical-stage biotechnology business REGENX is dedicated to enhancing lives via the healing power of gene therapy. It was established in 2008 as a public business. Headquarters are located in Rockville, Maryland. The business also works with areas in Japan, the USA, and the USA, including City, Rockville, Chuo-Ku, Thousand Oaks, and Tarrytown. The RGX-314 programme, which was started in 2022 and is being developed in partnership with AbbVie to treat wet AMD and diabetic retinopathy, is still on schedule to submit its first BLA in 2024.

9.Bayer AG-

One of the biggest pharmaceutical corporations in the world is Bayer AG, a global German pharmaceutical and biotechnology firm. Pharmaceuticals, consumer healthcare items, agricultural chemicals, seeds, and biotechnology products are just a few of the industries that Bayer, with its headquarters in Leverkusen, engages in. Barmen, Germany, was established on August 1st, 1863. Leverkusen, Germany, is home to its corporate headquarters, which employs 101,369 people worldwide. The R&D strategies of our divisions, which focus on the broad topics of Health and Agriculture segments, establish the company's research projects' specific areas of interest. Prior to special items, we spent €6,168 million on research and development in 2022.

*Definition-

Age-related macular degeneration (AMD) is a problem with your retina. It happens when a part of the retina called the macula is damaged.